{
  "abstract": "Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation that affects the patient outcomes. Published guidelines and consensus documents on RA-ILD or systemic autoimmune rheumatic disease/connective tissue disease-associated ILD have updated drug selection for RA-ILD; however, their meanings differ because they were developed using different methodologies for distinct clinical contexts. We compared these documents. Methotrexate (MTX)-associated acute/subacute pneumonitis should be distinguished from its effects on the development or progression of chronic fibrotic RA-ILD. Recent documents no longer consider RA-ILD alone a uniform contraindication for MTX, although severe, newly developed, or progressive ILD and the risk of drug-induced lung injury require reassessment. Abatacept and rituximab are often favored among biologic/targeted synthetic disease-modifying antirheumatic drugs, whereas the use of interleukin-6, Janus kinase, and tumor necrosis factor inhibitors varies. Drug selection should distinguish RA activity control from ILD-directed therapy and be individualized through multidisciplinary discussions considering the RA activity, ILD severity/progression and imaging, pulmonary toxicity, infection risk, and alternatives.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "name": "Hideaki Yamakawa"
    },
    {
      "name": "Masahiro Yokosawa"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7exp3brs36461.bib",
  "cited_by": 0,
  "doi": "10.2169/internalmedicine.8144-26",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8144-26/_article",
  "id": "7exp3brs36461",
  "issns": [
    "1349-7235",
    "0918-2918"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8144-26/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/general"
    ],
    [
      "openalex",
      "2740|Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis"
    ]
  ],
  "openalex": "W7204144973",
  "pdf_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8144-26/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-25",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7exp3brs36461.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "10.2169/internalmedicine.8144-26",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8144-26/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis",
      "subfield": "general"
    }
  ],
  "title": "Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease",
  "title_text": "Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/7exp3brs36461",
  "venue": "Internal Medicine",
  "versions": []
}